AstraZeneca

News

AstraZeneca bolts on blood pressure drug with CinCor takeove...

AstraZeneca has extended its cardiorenal pipeline with a $1.3 billion acquisition of CinCor Pharma, adding a late-stage blood pressure-lowering drug.

Oncology

Cancer control in a time of crisis - the pharmaphorum podcas...

During The Economist’s 8th Annual World Cancer Series congress in Brussels November last year, web editor Nicole Raleigh sat down to discuss the event and its themes with

News

FDA starts review of Sanofi, AZ antibody for RSV prevention

The clock has started ticking on the FDA's review of Sanofi and AstraZeneca's one-shot antibody to protect newborns and infants from respiratory syncytial virus (RSV), with a decision due i

News

EU approves AZ's Imfinzi plus chemo for advanced biliary tra...

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved in the

News

NICE expands breast cancer patient population eligible for E...

AstraZeneca and Daiichi Sankyo's Enhertu will become an option for hundreds more people with breast cancer in England and Wales, thanks to new guidance from NICE that will make it available

News

AZ's Imfinzi/Imjudo combo backed in EU for liver, lung cance...

AstraZeneca's oncology portfolio continues to deliver, with a recommendation for EU approval of its new Imfinzi/Imjudo immunotherapy combination heading a flurry of regulatory updates.

AstraZeneca bolts on blood pressure drug with CinCor takeove...

Cancer control in a time of crisis - the pharmaphorum podcas...

FDA starts review of Sanofi, AZ antibody for RSV prevention

EU approves AZ's Imfinzi plus chemo for advanced biliary tra...

NICE expands breast cancer patient population eligible for E...

AZ's Imfinzi/Imjudo combo backed in EU for liver, lung cance...

Harnessing the cell's own degradation machinery, with Benedi...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks